Added to YB: 2025-07-29
Pitch date: 2025-07-25
600535.SS [neutral]
Tasly Pharmaceutical Group Co., Ltd
-10.07%
current return
Author Info
Panda Perspectives helps manage a China Long-only and an Asia Pacific long/short funds with PACAT Capital Management in Hong Kong. Sign up for the newsletter.
Company Info
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China.
Market Cap
CNY 21.6B
Pitch Price
CNY 15.99
Price Target
N/A
Dividend
2.15%
EV/EBITDA
N/A
P/E
18.57
EV/Sales
2.22
Sector
Pharmaceuticals
Category
growth
Heritage to Hardware: Traditional Chinese Medicine’s Leap into Digital Health - Tasly Pharmaceutical Group
600535.SS (quick overview): China's leading TCM company combining traditional medicine with modern pharma standards. Strong R&D capabilities, advanced manufacturing facilities meeting international standards, and global market presence including FDA approvals. Financial performance shows consistent revenue growth from innovation and international expansion. Offers exposure to scientific TCM validation with global market access.
Read full article (2 min)